-

ELAN Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Elanco Animal Health Incorporated (NYSE: ELAN) Investors with Significant Losses to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco”).

On June 27, 2024, Elanco issued a press release providing updates to the company’s expected FDA approval timelines for its animal disease treatments, Zenrelia and Credelio Quattro. In the release, Elanco stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024, despite the company having previously set a launch timeline for the third quarter of 2024. Elanco also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, despite having previously set an approval timeline for the third quarter of 2024.

On this news, Elanco's stock price fell $3.69 per share, or 20.53%, to close at $14.28 per share on June 27, 2024.

If you are an Elanco investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ktmc.com. You can also click on the following link or paste it in your browser: https://www.ktmc.com/elanco-animal-health-incorporated-investigation?utm_source=PR&utm_medium=link&utm_campaign=elan&mktm=r

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

Contacts

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

Kessler Topaz Meltzer & Check, LLP

NYSE:ELAN

Release Versions

Contacts

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

More News From Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP Files a Class Action Lawsuit Against Volkswagen for Selling Vehicles With Defective Batteries that Catch Fire

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized class action litigation law firm, has filed a class action lawsuit against Volkswagen Aktiengesellschaft and Volkswagen Group of America, Inc. (“VW”), for breach of express warranty and other federal and state law violations. The complaint alleges that VW manufactured and sold certain vehicles – 2023-2025 Volkswagen ID.4s – which have defective batteries that may suddenly and unexpectedl...

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses. Alnylam Reports Disappointing Financial Results On July 30, 2026, Alnylam announced its second quarter 20...

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Capricor Therapeutics, Inc. (Capricor) (NASDAQ: CAPR) on behalf of those who purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026, inclusive. The lawsuit is filed in the United States District Court for the Southern District of California...
Back to Newsroom